Latest Pharma Insights
Obesity Research Is Surging Even As Overall Trial Volumes Decline
Obesity became the second most studied disease in 2025 with 184 trials – more than double the field's previous peak – as GLP-1 dominance reshapes a research landscape that has collapsed twice before on safety concerns.
In Vivo - June 16, 2026
Obesity became the second most studied disease in 2025 with 184 trials – more than double the field's previous peak – as GLP-1 dominance reshapes a research landscape that has collapsed twice before on safety concerns.
In Vivo - June 16, 2026
Mabworks, RemeGen Snag World-First Approvals For Renal Disorder, Sjögren’s Drugs In China
Mabworks' obinutuzumab and RemeGen's telitacicept help expand China’s growing list of global first-in-class drugs approved in the country before anywhere else, in this case for primary membranous nephropathy, and Sjögren’s disease/immunoglobulin A nephropathy, respectively.
Scrip - June 16, 2026
Mabworks' obinutuzumab and RemeGen's telitacicept help expand China’s growing list of global first-in-class drugs approved in the country before anywhere else, in this case for primary membranous nephropathy, and Sjögren’s disease/immunoglobulin A nephropathy, respectively.
Scrip - June 16, 2026
No Single Partner: How Leading Hospital Systems Are Building Multi-Vendor AI Ecosystems
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026
FDA’s Animal-Testing Alternatives Guidance Leaves Validation Bar Unsettled, Industry Says
Whether CDER draft guidance reaches CBER-regulated biologics is also among questions industry groups and sponsors have as they press US FDA to spell out validation and qualification expectations and show how new approach methodologies fit within a weight-of-evidence framework.
HBW Insight - June 16, 2026
Whether CDER draft guidance reaches CBER-regulated biologics is also among questions industry groups and sponsors have as they press US FDA to spell out validation and qualification expectations and show how new approach methodologies fit within a weight-of-evidence framework.
HBW Insight - June 16, 2026
Mabworks, RemeGen Snag World-First Approvals For Renal Disorder, Sjögren’s Drugs In China
Mabworks' obinutuzumab and RemeGen's telitacicept help expand China’s growing list of global first-in-class drugs approved in the country before anywhere else, in this case for primary membranous nephropathy, and Sjögren’s disease/immunoglobulin A nephropathy, respectively.
Scrip - June 16, 2026
Mabworks' obinutuzumab and RemeGen's telitacicept help expand China’s growing list of global first-in-class drugs approved in the country before anywhere else, in this case for primary membranous nephropathy, and Sjögren’s disease/immunoglobulin A nephropathy, respectively.
Scrip - June 16, 2026
No Single Partner: How Leading Hospital Systems Are Building Multi-Vendor AI Ecosystems
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026
Across prominent health systems, a structural pattern is emerging: Projects like the Cleveland Clinic’s five-vendor pilot and Mayo’s proprietary frontier model indicate a trend toward multi-vendor strategies.
Medtech Insight - June 16, 2026
FDA’s Animal-Testing Alternatives Guidance Leaves Validation Bar Unsettled, Industry Says
Whether CDER draft guidance reaches CBER-regulated biologics is also among questions industry groups and sponsors have as they press US FDA to spell out validation and qualification expectations and show how new approach methodologies fit within a weight-of-evidence framework.
HBW Insight - June 16, 2026
Whether CDER draft guidance reaches CBER-regulated biologics is also among questions industry groups and sponsors have as they press US FDA to spell out validation and qualification expectations and show how new approach methodologies fit within a weight-of-evidence framework.
HBW Insight - June 16, 2026
Aurobindo Looks To Bolster French Footprint With Facility Purchase
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Aurobindo has enhanced its operations in France by acquiring a former Bristol Myers Squibb manufacturing facility through its local Arrow subsidiary.
Generics Bulletin - June 15, 2026
Formycon Started 2026 On A Strong Financial Note – Can It Be Maintained?
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
With its full-year guidance now confirmed, Formycon's numbers are moving in the right direction after a difficult 2025.
Generics Bulletin - June 15, 2026
Brazil Aligns With Global Consensus On Biosimilar Switching
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Anvisa says biosimilar switching can be done safely under approved conditions, aligning Brazil with international regulators while stressing monitoring, traceability and safeguards against unplanned changes.
Generics Bulletin - June 15, 2026
Generics Pricing Pact Gives Canada Two More Years
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
Canada’s pCPA and CGPA have extended their national generic-drug pricing framework to 2028, preserving cost-control measures, price predictability and supply certainty for medicines reimbursed by public drug plans.
Generics Bulletin - June 15, 2026
Obesity Research Is Surging Even As Overall Trial Volumes Decline
Obesity became the second most studied disease in 2025 with 184 trials – more than double the field's previous peak – as GLP-1 dominance reshapes a research landscape that has collapsed twice before on safety concerns.
In Vivo - June 16, 2026
Obesity became the second most studied disease in 2025 with 184 trials – more than double the field's previous peak – as GLP-1 dominance reshapes a research landscape that has collapsed twice before on safety concerns.
In Vivo - June 16, 2026